Moderna (NASDAQ:MRNA) Stock Price Down 7.6% – Time to Sell?

Shares of Moderna, Inc. (NASDAQ:MRNA) dropped 7.6% during mid-day trading on Friday . The company traded as low as $49.58 and last traded at $49.75. Approximately 3,560,598 shares changed hands during trading, a decline of 72% from the average daily volume of 12,508,803 shares. The stock had previously closed at $53.83.

Key Stories Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Settlement clears a multi‑year patent fight, removing a major legal overhang that had weighed on valuation — the market has reacted positively even though the company must pay to resolve claims. Moderna rises on $2.25 billion settlement, clearing COVID vaccine patent dispute overhang
• Positive Sentiment: Coverage confirms Moderna will pay up to $2.25B (reports vary on final amounts), which reduces litigation uncertainty that had capped upside — investors view clarity as a catalyst despite the cash cost. Moderna to pay up to $2.25B to end mRNA vaccine patent fight
• Positive Sentiment: Analyst/coverage optimism: a buy initiation highlights multiyear growth drivers (mNEXSPIKE approvals, flu/combination vaccines, oncology programs) and presents a constructive view on narrowing losses and 2026 guidance. The Sun Will Shine On Moderna Again – Initiating With A Buy
• Neutral Sentiment: Retail and momentum: Reddit-driven buying and recent volatility have lifted shares YTD, creating short‑term catalyst-driven spikes but also raising the risk of sharp pullbacks. Reddit Traders Are Cheering Moderna While Bears Watch The Cash Burn
• Neutral Sentiment: Longer-term debate: pieces weighing whether Moderna is still a “COVID company” vs. an oncology/mRNA platform argue the stock will hinge on upcoming Phase 3 clinical readouts — big upside if oncology data holds, big downside if it disappoints. Moderna Stock (MRNA): Is It a Buy Now? 7 Questions After the Crash
• Neutral Sentiment: Market take on volatility: general coverage grouping Moderna with other volatile names notes a bounce from lows but emphasizes differing fundamentals and drivers — useful context but not an immediate catalyst. These 3 Stocks Just Bounced From Lows — What Wall Street Thinks Comes Next
• Negative Sentiment: Regulatory uncertainty: a CNBC piece highlights recent FDA reversals and denials across drug applications — it cites an instance where the FDA initially refused to review Moderna’s flu shot before reversing course, underscoring the regulatory risk that can weigh on near‑term valuation. FDA reversals leave investors worrying about the fates of other experimental drugs

Analysts Set New Price Targets

Several brokerages recently issued reports on MRNA. Morgan Stanley set a $30.00 price objective on Moderna in a report on Monday, February 16th. Citigroup reaffirmed a “neutral” rating on shares of Moderna in a research note on Monday, February 16th. UBS Group reiterated a “neutral” rating and issued a $36.00 price objective on shares of Moderna in a research report on Monday, February 16th. TD Cowen reissued a “hold” rating on shares of Moderna in a research note on Thursday, January 29th. Finally, The Goldman Sachs Group lifted their target price on shares of Moderna from $36.00 to $41.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 17th. Two analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and five have assigned a Sell rating to the stock. Based on data from MarketBeat, Moderna currently has a consensus rating of “Reduce” and an average target price of $32.33.

Moderna Trading Down 5.4%

The stock has a market cap of $20.11 billion, a PE ratio of -7.01 and a beta of 1.29. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.22 and a current ratio of 3.29. The business has a 50-day moving average of $42.70 and a 200 day moving average of $32.06.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Friday, February 13th. The company reported ($2.11) EPS for the quarter, topping analysts’ consensus estimates of ($2.79) by $0.68. The business had revenue of $678.00 million during the quarter, compared to the consensus estimate of $611.14 million. Moderna had a negative net margin of 145.16% and a negative return on equity of 30.15%. The company’s quarterly revenue was down 33.2% compared to the same quarter last year. During the same period in the previous year, the firm posted ($2.91) earnings per share. Equities research analysts predict that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Insider Activity at Moderna

In related news, President Stephen Hoge sold 160,009 shares of the stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $48.84, for a total transaction of $7,814,839.56. Following the transaction, the president directly owned 1,457,427 shares in the company, valued at approximately $71,180,734.68. This represents a 9.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Noubar Afeyan sold 23,853 shares of the company’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $29.48, for a total transaction of $703,186.44. Following the transaction, the director directly owned 3,924 shares of the company’s stock, valued at approximately $115,679.52. This represents a 85.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 184,366 shares of company stock valued at $8,531,936 over the last ninety days. 10.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Moderna

A number of large investors have recently bought and sold shares of MRNA. Caitong International Asset Management Co. Ltd grew its stake in shares of Moderna by 21.9% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,153 shares of the company’s stock valued at $63,000 after buying an additional 387 shares during the period. Sankala Group LLC acquired a new position in Moderna in the fourth quarter valued at $240,000. Virtu Financial LLC purchased a new stake in Moderna during the fourth quarter valued at about $2,425,000. Hamilton Wealth LLC purchased a new stake in Moderna during the fourth quarter valued at about $3,098,000. Finally, Corient Private Wealth LLC increased its stake in Moderna by 143.3% during the fourth quarter. Corient Private Wealth LLC now owns 68,256 shares of the company’s stock worth $2,013,000 after acquiring an additional 40,202 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.